NEWS

Simcere Pharmaceuticals Realized Overseas Authorization of Autoimmune New Drugs for Nearly US $0.5 billion

Release time:

2022-09-30 14:12

2022Year9Month29day,Simcere PharmaceuticalsandAlmirallThe company announced that it has developed aautoimmune drug candidatesIL-2Mutant fusion proteinSIM0278Enter into an exclusive license agreement.AlmirallThe company will be developed and commercialized outside of Greater China.SIM0278Exclusive rights to all indications, Simcere will retain all rights to the product in Greater China.

Under the terms of the agreement, Simcere will receiveAlmirallCompany1500million heads of state paymentand charge up to based on possible outcomes for multiple indications.4.92$100 million in development and commercial milestone payments(including some sales milestones);There is also a low double-digit percentage rate based on future sales of the product in the agreed area..

This external authorizationSIM0278It is a regulatory development based on its own protein engineering technology platform.TCells (Treg) Preference Interleukin2The fusion protein (IL-2 mu-Fc). It will carry a specific mutationIL-2with antibodiesFcterminal fusion, significantly prolonging the molecular half-life and improve receptor specificity and affinity, can selectively activateTregcells, while almost no activation effectTcells orNKcells, so as to restore the body's immune balance.In multiple preclinical disease models,SIM0278Has shown good curative effect, has become“best-in-class”of potential. it has been learned that,The product will be developed into a subcutaneous injection preparation, which is expected to be used to treat a variety of autoimmune diseases.IL-2is an immune response-related cytokine, which is important for immuneTcell proliferation activation has an important effect. It has previously been targeted.IL-2The related products of the Company have been approved for marketing as anti-cancer drugs, and such products have been approved for marketing through the promotion effect.TCell proliferation to achieve anti-cancer effect. The study also found that,IL-2activation effect at different concentrationsTCellular (immune acceleration) and pro-regulatoryTDual function of cells (immune brakes).

At present, the world has a number of large pharmaceutical companies are actively involved inIL-2Mutant fusion protein self-immunity treatment project.2021Year2month,Mercader (MSD)announced that it will be based on a total of approximately18.5Billions of dollars in the amount of acquisitionPandion Therapeutics,thereby obtainingPandion TherapeuticsThe main therapy in research:IL-2mutantPT101.2022Year5month,AbbVie (AbbVie)AgainCousensThe company is close.5000US $10,000 Cooperation to Develop TargetingTregofIL-2Mutant Protein ProjectCUG252. In addition, there areAmjin (Amgen) and other companiesis also being developed in early clinicalIL-2Mudant fusion proteins.

It can be seen that owning the intellectual property rights of core technologies in a certain field is an important bargaining chip for enterprises to find strong cooperative development partners in this field and obtain follow-up R & D funds; this puts forward requirements for the far-sightedness and frontier of the enterprise's intellectual property layout.

Self, il-2, cell, immune, company, fusion, development, product, protein, pharmaceutical